Georg Schett co-founds antibody biotech, skips CAR-T
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Georg Schett, a German researcher who has pioneered the use of CAR-T therapy in autoimmune disease over the last five years, is co-founding a biotech company for the first time.
- Schett's work has shown CAR-T therapy can be used to reset patients' immune systems, establishing him as a leading figure in the autoimmune CAR-T field.
- The new company has no immediate plans to work in CAR-T, instead outlining plans around antibody therapies despite its founder's signature expertise.
- Schett currently serves as a scientific adviser on a half-dozen startup advisory boards in the autoimmune disease space, a role that precedes his move to co-found a company.
- The article detailing the company's antibody plans and Schett's transition from adviser to founder is exclusive to STAT+ subscribers.
Why it matters: After five years of building the autoimmune CAR-T field, Schett is launching a company that explicitly avoids CAR-T — a notable signal that even the modality's strongest proponents may see antibody approaches as the more scalable or commercially viable path for autoimmune disease.
Ask SkimNews
